Analyst confidence swells following positive FDA alignment on the company's pivotal gene therapy trial for Rett Syndrome.
Permanent J-Code from CMS aims to streamline reimbursement and broaden patient access for its graft-versus-host disease treatment.
Genentech's Tecentriq combination therapy is the first maintenance treatment for extensive-stage small cell lung cancer, a significant advance in a hard-to-treat disease.
The broad cryptocurrency rally sees XRP top $3 and Ethereum reclaim $4,500 as bullish momentum returns to the market.
JPMorgan amplifies the rally, raising its year-end price target for the cryptocurrency to $165,000, citing significant undervaluation.
Investor optimism surges on the back of OpenAI's ambitious Stargate project, overriding concerns about a potential US government shutdown.
Regulators express significant doubts over the company's lead drug candidate, avacopan, sparking a massive investor sell-off.
The new oral treatment addresses chronic spontaneous urticaria in patients unresponsive to antihistamines, driving shares up over 2.7%.